Introduction: The objective of this study was to describe a pharmacokinetic–pharmacodynamic (PK/PD) approach for determination of a rational dosage of ampicillin (AMP) and depletion of the antibiotic residues in milk after intramammary administration to cows.

Introduction: The objective of this study was to describe a pharmacokinetic–pharmacodynamic (PK/PD) approach for determination of a rational dosage of ampicillin (AMP) and depletion of the antibiotic residues in milk after intramammary administration to cows.Material and Methods: The cows came from different farms from the Lublin Province area. They (n = 9) received 5 g of the drug, containing 75 mg of AMP sodium in physiological solution, through a syringe tube by intramammary administration. Following single intramammary administration, the milk samples (5 mL) were collected after 2, 4, 6, 8, 10, 24, 36, 48, and 60 h. The liquid chromatography-mass spectrometry analysis was performed on the Agilent 1200 system connected to an AB Sciex API 4000™ mass spectrometer. The pharmacokinetic analysis of the concentrations of the antibiotic in milk was performed using software Phoenix® WinNonlin® 6.4. Calculations were made in non-compartmental (slopes, highest, amounts, and moments) and compartmental analysis.Results: The pharmacokinetic characteristics of AMP after intramammary administration indicate rapid elimination of the drug from milk. The mean residence time had a several-fold lower value than the designated elimination half-life and amounts to only 3.4 h. The concentration of the drug in the milk dropped relatively quickly and the process was very dynamic.Conclusion: The conducted research confirms the rationale of using the PK/PD model in order to verify the dosing regimen for other antibiotic groups and various indicators of the applied PK/PD model.

Amikacin is a semisynthetic derivative of kanamycin and primarily active against aerobic Gram-negative-pathogens with limited activity against Gram-positive bacteria. Meager study was reported on pharmacokinetic data on multi-days administration of amikacin. Hence, pharmacokinetics study was done in five clinically healthy goats (n = 5), after intravenous bolus injection of amikacin sulfate at the dose rate of 10 mg/kg body weight daily for three consecutive days. The amikacin concentrations in plasma and pharmacokinetics-parameters were analyzed by using microbiological assay technique and non-compartmental open-model, respectively. The mean peak plasma concentrations (Mean ± SD) of amikacin at time zero (Cp∨0) was 114.19 ± 20.78 and 128.67 ± 14.37 ㎍/mL, on day 1st and 3rd, respectively. The mean elimination half-life (t∧1/2ke) was 1.00 ± 0.28 h on day 1st and 1.22 ± 0.29 h on day 3rd. Mean of area under concentration-time curve (AUC∧0→∞) was 158.26 ± 60.10 and 159.70 ± 22.74 ㎍.h/mL, on day 1st and 3rd respectively. The total body clearance (Cl∧B) and volume of distribution at steady state (Vdss) on day 1st and 3rd were Cl∧B = 0.07 ± 0.02 and 0.06 ± 0.01 L/h.kg and Vdss = 0.10 ± 0.03 and 0.11 ± 0.05 L/kg, respectively. No-significant difference was noted in both drug-plasma concentration and pharmacokinetics-parameters, respectively. Amikacin concentration in plasma was found higher up-to 4 h and 6 h onward on down-ward trends favour to reduce toxicity. Which also support the pharmacokinetic-pharmacodynamic way of dosing of aminoglycosides and hence, amikacin may be administered 10 mg/kg intravenously daily to treat principally Gram-negative pathogens and limitedly Gram-positive-pathogens.

Combination therapy of antibiotics is leading to improved efficacy or safety profiles with decrease emergence of bacterial resistance. Because of this benefit, many of antibacterial combinations have been used in veterinary practice for the past few decades. The purpose of this study was to examine the in vitro activity of an amoxicillin alone and in combination with other antibiotics against pathogenic bacteria of fish origin. Based on the fractional inhibitory concentration (FIC) index (FIC less-than or equal to 0.5), a synergistic interaction was shown in combination of florfenicol with amoxicillin or cefuroxime. The combination of florfenicol and amoxillin showed higher antibacterial activity than that of florfenicol and cefuroxime. Ratio of amoxicillin and florfenicol in combination was 1 : 1, which showed the antibacterial activity against bacterial isolates of fish as compared with other ratios. A synergetic effect of the combination (amoxicillin and florfenicol) was further confirmed in the time-kill curve study. The study showed a better in vitro antibacterial activity of a 1 : 1 combination of amoxicillin and florfenicol than the individual antibacterial against bacterial isolates of fish. In conclusion, the combination of florfenicol and amoxicillin may serve as a potential antibacterial therapy in fishes infected pathogenic bacteria.

The present study was planned to evaluate the bioequivalence of two commercial formulations of enrofloxacin, which have been marketed as 10% injectable solution after intramuscular administration at a single dose of 2.5 mg/kg body weight to 12 clinically healthy goats The study was carried out on the basis of crossover design. The two formulations were: Baytril as a reference product and Spectrama Vet as a test product. The plasma concentrations of enrofloxacin were measured by high performance liquid chromatography (HPLC) with UV detector. The pharmacokinetics of that data was performed using non-compartmental analysis. The maximum plasma concentration (Cmax), time to reach peak concentration (Tmax), area under concentration-time curve (AUC), elimination half-life (t0.5el) were 1.14 and 1.05 μg/mL, 0.79 and 0.83 h, 5.70 and 5.79 μg.h/mL, 5.19 and 5.39 h for Baytril and Spectrama Vet, respectively. The 90% confidence interval for the mean ratio of Tmax, Cmax and AUC were 94.72~116.2, 87.88~97.16 and 86.44~118.72%, respectively. These values falls within the European Medicines Agency bioequivalence acceptance range of 80~125% for both Tmax and AUC and between 75~133% for Cmax. In conclusion, Spectrama-Vet is bioequivalent to Baytril and both products can be used as interchangeable drug in veterinary medicine practice.

We have studied pharmacokinetics of a new anti-human immunodeficiency virus (HIV) agent VP-0501 and its amino acid prodrug VP-0501AL which is designed to improve oral bioavailability. After oral administration at 100 mg/kg dose in rats (n=4), VP-0501 was not detectable in plasma (less than 50 ng/ml), while after the administration of VP-0501AL, VP-0501 was quantitatively detected, at least for 8 hrs, with Cmax of ca. 2.5 μg/ml and AUC of 8 hr*μg/ml.

Sodium hyaluronate reduces adhesions after tendon repair in rodents and dogs, and has been used in limited clinical trials in people. To evaluate its effect on tendon healing and adhesion formation in horses and to compare these effects with those of a compound of similar viscoelastic properties, a study was performed in horses, using a model of collagenase injection in the flexor tendons within the digital sheath. Eight clinically normal horses were randomly allotted to 2 groups. Adhesion formation between the deep digital flexor tendon and the tendon sheath at the pastern region was induced in the forelimbs of all horses. Using tenoscopic control, a 20-gauge needle was inserted into the deep digital flexor tendon of horses under general anesthesia and 0.2 ml of collagenase (2.5 mg/ml) was injected. The procedure was repeated proximally at 2 other sites, spaced 1.5 cm apart. A biopsy forceps was introduced, and a 5-mm tendon defect was created at each injection site. Group-A horses had 120 mg of sodium hyaluronate (NaHA) gel injected into the tendon sheath of one limb. Group-B horses had methylcellulose gel injected at the same sites. The contralateral limbs of horses in both groups served as surgical, but noninjected, controls. Horses were euthanatized after 8 weeks of stall rest. Ultrasonographic evaluation revealed improved tendon healing after NaHA injection, but no difference in peritendinous adhesion formation. Tendon sheath fluid volume and hyaluronic acid (HA) content were greater in NaHA-treated limbs. Gross pathologic examination revealed considerably fewer and smaller adhesions when limbs were treated with NaHA. However, significant difference in pull-out strengths was not evident between NaHA-treated and control limbs. Histologically, the deep digital flexor tendon from the NaHA-treated limbs had reduced inflammatory cell infiltration, improved tendon structure, and less intratendinous hemorrhage. Treatment with methylcellulose had no significant effect on tendon healing, adhesion size, quantity, or strength or on the volume and composition of the tendon sheath fluid. Sodium hyaluronate, administered intrathecally, appears to have a pharmaceutically beneficial action in this collagenase-induced tendinitis and adhesion model in horses.

Edible bird's nest (EBN)is made from the saliva of swiftlet from the Aerodramus species. It is one of the most widely consumed traditional health food by the Chinese community due to its claimed medicinal value. EBN contains glycoproteins with abundance of sialic acid (SA). EBN with higher SA content has a potential to command for higher price. The objective of this study was to determine and compare free SA content of EBN collected from Johor and Kelantan. A total of 23 and 30 of raw and unprocessed EBN samples were obtained from Kelantan and Johor, respectively. SA from EBN samples were analysed using LC-MS/MS. Johor showed higher content of free SA with the value of 135.04 ± 29.60 mg/kg compared to Kelantan which has a value of 95.55 ± 25.6 mg/kg. Highest content of free SA was found in EBN from Pontian district, Johor.

For the determination of efficiency of a new produced in the Republic of Belarus preparation Ehkvikar there was modeled a test with a diaphoresis of guinea pigs by means of their staying in a thermostat at a temperature of 45-50 deg C in course of 30 minutes. Before and after the test there was taken a blood test for its analysis. Results of the experiment showed that together with sudo the animals lost 1-2 % of their body. There was stated the increasing of all blood corpuscles as well as lowering in 1,3-1,47 times of such elements as chlorine, sodium, potassium, and also T lymphocytes and bursa-derived lymphocytes. Application Ehkvikar promoted the stabilization of biochemical and morphological parameters of blood, and also the immune status of laboratory animals. Thus, Ehkvikar preparation promoted the compensation of losses of electrolytes with sudor of guinea pigs and in future can be studied by an example of horses for completion of electrolytes losses in the conditions of increased physical exercises.